This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: February 27, 2009
Last updated: November 1, 2016
Last verified: November 2016
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy.

Condition Intervention Phase
Non-Hodgkin's Lymphoma, Solid Cancers Drug: GDC-0980 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase I, Dose-escalation Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors and Non-hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Occurrence of adverse events [ Time Frame: Length of study ]
  • Occurrence of dose-limiting toxicities [ Time Frame: Length of study ]
  • Occurrence of Grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0980 [ Time Frame: Length of study ]
  • PK parameters after doses of GDC-0980 [ Time Frame: Length of study ]

Secondary Outcome Measures:
  • Best overall response, duration of objective response, and progression-free survival for patients with measurable disease according to RECIST [ Time Frame: Length of study ]
  • PET response for patients with detectable FDG tumor uptake at baseline [ Time Frame: Length of study ]

Enrollment: 38
Study Start Date: May 2009
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: GDC-0980
Escalating repeating dose


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically documented, incurable, locally advanced or metastatic solid malignancies, or NHL without leukemic phase, that has progressed despite standard of care therapy or for which there is no standard therapy of proven clinical benefit
  • A biopsy-accessible lesion from which tissue can be obtained safely
  • Evaluable or measurable disease per RECIST and/or the following: prostate cancer patients with non-measurable disease are eligible if they have two rising prostate-specific antigen (PSA) levels that meet the PSA Working Group criteria for progression prior to initiation of study treatment; ovarian cancer patients with non-measurable disease are eligible if they have two rising CA-125 levels greater than the ULN >= 2 weeks apart prior to initiation of study treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening
  • Life expectancy >= 12 weeks
  • Adequate hematologic and organ function within 28 days before initiation of GDC-0980
  • Documented willingness to use an effective means of contraception for both men and women while participating in the study
  • For patients participating in DCE-MRI assessments: at least one metastatic lesion measuring >/= 3 cm in the liver or >/= 2 cm elsewhere (lung and mediastinum lesions are ineligible) in at least one dimension (on CT scan)

Exclusion Criteria:

  • Leptomeningeal disease as the only manifestation of the current malignancy
  • History of Type 1 or 2 diabetes mellitus requiring regular medication
  • Grade >=2 hypercholesterolemia or hypertriglyceridemia
  • Malabsorption syndrome or other condition that would interfere with enteral absorption
  • Known untreated malignancies of the brain or spinal cord, or treated brain metastases that are not radiographically stable for >= 3 months
  • Congenital long QT syndrome or screening QTc > 470 msec
  • Active congestive heart failure or ventricular arrhythmia requiring medication
  • Ejection fraction that is <50% or is below the LLN (whichever is higher), as determined by echocardiogram or MUGA scan
  • Active infection requiring IV antibiotics
  • Requirement for any daily supplemental oxygen
  • DLCO < 50% of predicted value corrected for hemoglobin and alveolar volume
  • Uncontrolled hypomagnesemia
  • Hypercalcemia requiring continued use of bisphosphonate therapy
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Uncontrolled ascites requiring frequent paracentesis
  • Known HIV infection
  • Any other diseases, active or controlled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patients at high risk from treatment complications
  • Significant traumatic injury within 4 weeks of Day 1
  • Major surgical procedure within 4 weeks prior to initiation of GDC-0980
  • Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives, or GnRH agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within 3 weeks prior to initiation of GDC-0980
  • Palliative radiation to bony metastases within 2 weeks prior to initiation of GDC-0980
  • Need for chronic corticosteroid therapy of >=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant
  • Treatment with an investigational agent within 4 weeks prior to initiation of GDC-0980
  • Unresolved toxicity from prior therapy except for alopecia and Grade 1 peripheral neuropathy
  • Pregnancy or lactation
  • For patients participating in DCE-MRI assessments, any contraindication to MRI examination
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00854126

United States, Massachusetts
Boston, Massachusetts, United States, 02115
Villejuif, France, 94805
United Kingdom
Manchester, United Kingdom, M20 4BX
Sponsors and Collaborators
Genentech, Inc.
Study Director: Mika Derynck, M.D. Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT00854126     History of Changes
Other Study ID Numbers: PIM4605g
MP00881 ( Other Identifier: Hoffmann-La Roche )
Study First Received: February 27, 2009
Last Updated: November 1, 2016

Keywords provided by Genentech, Inc.:
Solid Tumors
Carcinogenic Tumors

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on September 21, 2017